CC4047-MM-007: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidamide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in subjects with Relapsed or Refractory Multiple myeloma The purpose of this study is to see how well the combination of pamalidomide, bortezomib and dexamethasone works compared to the combination of bortezomib and dexamethasone.

Clinical Program: Malignant Hematology Program
Primary Sponsor: Celgene
Principal Investigator: Imad Tabbara
Contact Info: 202-741-2981